Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea

Table 1 Baseline characteristics and Helicobacter pylori eradication rates due to moxifloxacin triple therapy

	Moxifloxacin-containing triple therapy as second line	P value1
Total eradication rate	73.9% (195/264)
Clinical factors
Gender		0.794
Male	74.6% (94/126)
Female	73.2% (101/138)
Age		0.965
< 45	74.2% (23/31)
≥ 45	73.8% (172/233)
Smoking		0.575
Current smoker	77.1% (37/48)
Non-smoker	73.1% (158/216)
Alcohol		0.356
Current drinker	69.4% (43/62)
Non-drinker	75.2% (152/202)
Comorbidity
HTN	69.4% (34/49)	0.429
DM	90.5% (19/21)	0.076
Disease status		0.046
Peptic ulcer (DU/GU)	82.9% (58/70)
Non-ulcer	70.6% (137/194)

¹Pearson's χ² test. HTN: Hypertension; DM: Diabetes mellitus; DU: Duodenal ulcer; GU: Gastric ulcer.

Table 2 Baseline characteristics according to first line therapies n (%)

	Standard triple therapy	Bismuth quadruple therapy	Sequential therapy	Concomitant therapy	P value1
Mean age ± SD (yr)	58.1 ± 11.6	58.5 ± 11.4	56.1 ± 11.5	56.9 ± 11.3	0.591
Male/Female (n)	72/86	10/18	20/21	24/13	0.150
Smoking (n)	28 (17.7)	4 (13.8)	8 (19.5)	8 (21.6)	0.904
Alcohol (n)	35 (22.2)	7 (24.1)	10 (24.4)	10 (27)	0.851
HTN (n)	34 (21.5)	5 (17.2)	6 (14.6)	4 (10.8)	0.451
DM (n)	14 (8.9)	3 (10.3)	2 (4.9)	2 (5.4)	0.845
Endoscopic finding (n)					-
DU/GU	55	1	6	8	-
CAG	66	18	13	12	-
IM	23	1	5	3	-
Erosive gastritis	30	9	18	15	-
MALT lymphoma	0	0	2	0	-

¹Pearson's χ² test. HTN: Hypertension; DM: Diabetes mellitus; DU: Duodenal ulcer; GU: Gastric ulcer; CAG: Chronic atrophic gastritis; IM: Intestinal metaplasia; MALT: Mucosa associated lymphoid tissue.

Table 3 Adverse events n (%)

	First-line therapy	Moxifloxacin-containing triple therapy
Diarrhea	21 (7.9)	25 (9.4)
Nausea/Vomiting	14 (5.3)	23 (8.7)
Abdominal pain	14 (5.3)	11 (4.2)
Taste distortion	19 (7.2)	4 (1.5)
Dizziness	3 (1.1)	1 (0.4)
Dyspepsia	3 (1.1)	5 (1.9)
Total	76 (28.7)	61 (23.1)

Table 4 Helicobacter pylori eradication rates due to 14-d moxifloxacin triple therapy according to proton pump inhibitors

	Esomeprazole	Rabeprazole	P value1
ITT analysis
% Eradication (ratio)	73.8% (127/172)	63.6% (28/44)	0.180
95%CI	66.8-79.8	48.9-76.2
PP analysis
% Eradication (ratio)	80.9% (127/157)	65.1% (28/43)	0.028
95%CI	74.0-86.3	50.2-77.6

¹Pearson's χ² test. ITT: Intention to treat; PP: Per protocol.